LPA2 antagonist 1

• CAT Number: I000131
• CAS Number: 1017606-66-4
• Molecular Formula: C20H23Cl2N5O2S2
• Molecular Weight: 500.457
• Purity: ≥95%
• Synonyms: (S)-N-(1-(4-((3,4-dichlorophenyl)sulfonyl)piperazin-1-yl)propan-2-yl)-7-methylthieno[3,2-d]pyrimidin-4-amine
• Target: LPL Receptor
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IC50: > 30 uM [1]
• IUPAC Name: N-[(2S)-1-[4-(3,4-dichlorophenyl)sulfonylpiperazin-1-yl]propan-2-yl]-7-methylthieno[3,2-d]pyrimidin-4-amine
• InChI: InChI=1S/C20H23Cl2N5O2S2/c1-13-11-30-19-18(13)23-12-24-20(19)25-14(2)10-26-5-7-27(8-6-26)31(28,29)15-3-4-16(21)17(22)9-15/h3-4,9,11-12,14H,5-8,10H2,1-2H3,(H,23,24,25)/t14-/m0/s1
• InChIKey: BPRNMVDTWIHULJ-AWEZNQCLSA-N
• SMILES: CC1=CSC2=C1N=CN=C2NC(C)CN3CCN(CC3)S(=O)(=O)C4=CC(=C(C=C4)Cl)Cl

LPA2 antagonist 1(CAT: I000131) is a selective inhibitor targeting lysophosphatidic acid receptor 2 (LPA2) activity. By specifically blocking the functioning of LPA2, this compound holds the potential in modulating cellular responses mediated by LPA2, which is involved in various physiological and pathological processes. As a result, LPA2 antagonist 1 may offer therapeutic avenues for conditions where LPA2 signaling plays a significant role, making it a candidate for research and development in the field of molecular pharmacology and related studies.

Reference

[1]. Beck HP, et al. Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1037-41.
[2]. Kozian DH, et al. Selective non-lipid modulator of LPA5 activity in human platelets. Bioorg Med Chem Lett. 2012 Aug 15;22(16):5239-43.